Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Preventing respiratory syncitial virus bronchiolitis.

× No keyword cloud information.

11 in total

1. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.

Authors: T P Stevens; R A Sinkin; C B Hall; W M Maniscalco; K M McConnochie
Journal: Arch Pediatr Adolesc Med Date: 2000-01

2. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort.

Authors: S J Clark; M W Beresford; N V Subhedar; N J Shaw
Journal: Arch Dis Child Date: 2000-10 Impact factor: 3.791

3. Ribavirin and bronchiolitis: variation in use in the UK.

Authors: T D Allport; E G Davies; C Wells; M Sharland
Journal: Arch Dis Child Date: 1997-04 Impact factor: 3.791

4. Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin.

Authors: M Thomas; A Bedford-Russell; M Sharland
Journal: Arch Dis Child Date: 2000-08 Impact factor: 3.791

Review 5. Prevention of respiratory syncytial virus infection with palivizumab.

Authors: M Thomas; A Bedford-Russell; M Sharland
Journal: Monaldi Arch Chest Dis Date: 2000-08

Review 6. Immunoglobulin for preventing respiratory syncytial virus infection.

Authors: E E Wang; N K Tang
Journal: Cochrane Database Syst Rev Date: 2000

7. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors:
Journal: Pediatrics Date: 1998-09 Impact factor: 7.124

8. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group.

Authors:
Journal: Pediatrics Date: 1997-01 Impact factor: 7.124

9. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.

Authors: S Joffe; G T Ray; G J Escobar; S B Black; T A Lieu
Journal: Pediatrics Date: 1999-09 Impact factor: 7.124

10. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.

Authors:
Journal: Pediatrics Date: 1998-11 Impact factor: 7.124

4 in total

Review 1. Respiratory syncytial virus bronchiolitis.

Authors: Alexander K C Leung; James D Kellner; H Dele Davies
Journal: J Natl Med Assoc Date: 2005-12 Impact factor: 1.798

2. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.

Authors: T Heikkinen; H Valkonen; L Lehtonen; R Vainionpää; O Ruuskanen
Journal: Arch Dis Child Fetal Neonatal Ed Date: 2005-01 Impact factor: 5.747

3. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection.

Authors: A Greenough; S Cox; J Alexander; W Lenney; F Turnbull; S Burgess; P A Chetcuti; N J Shaw; A Woods; J Boorman; S Coles; J Turner
Journal: Arch Dis Child Date: 2001-12 Impact factor: 3.791

4. Enhanced surfactant protein and defensin mRNA levels and reduced viral replication during parainfluenza virus type 3 pneumonia in neonatal lambs.

Authors: Branka Grubor; Jack M Gallup; David K Meyerholz; Erika C Crouch; Richard B Evans; Kim A Brogden; Howard D Lehmkuhl; Mark R Ackermann
Journal: Clin Diagn Lab Immunol Date: 2004-05

4 in total